Inadvertent higher rate atrial pacing after dual chamber pacemaker implantation - What is the underlying mechanism?

Unexplained change in parameters, despite good lead positions or odd ECG patterns following implant should lead to suspicion of lead swap, amongst other possibilities. An easy way to confirm this is by paying careful attention to device EGMs and recording the ECG by switching off one channel, and pacing single channel (in either AAI or VVI mode).

Use of strain imaging to detect subtle myocardial involvement in post COVID-19 patients: An Indian perspective.

Background: The study assessed Global longitudinal strain imaging (GLS) to detect subtle myocardial dysfunction among patients clinically recovered from COVID-19.

Methods: All patients (n = 101 76 % males, mean age 55.45 ± 11.

RAdiation Dose Attenuation using RADPAD in CATH lab for primary and secondary operators - RADAR-CATH STUDY.

Background: Radiation injury is an important concern for interventional cardiologists and needs to be addressed. RADPAD is a radiation protection drape that has been shown to reduce the radiation exposure of the primary operator (PO). While Indian data on radiation exposure of the PO in the cath lab are scarce, the exposure of the secondary operator (SO) is even less well studied.

A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation.

Objectives: Ivabradine may have a role in rate control of atrial fibrillation (AF) due to effects on HCN channels in AV node. We studied role of Ivabradine in rate control of rheumatic AF.

Methods: 80 patients, rheumatic AF, HR > 100 bpm (age 47 ± 11 yrs, AF duration 6.

Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? - New insights from RIVER trial.

Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a large trial where rivaroxaban was found to be non-inferior to warfarin on head-to-head basis. This commentary discusses the various aspects related to oral anticoagulation in bioprosthetic valve recipients in the light of recent clinical evidence.